Cost-effectiveness of blinatumomab for the treatment of B‑precursor acute lymphoblastic leukemia pediatric patients with high‑risk first‑relapse in Mexico
Open Access
- 22 August 2024
- journal article
- research article
- Published by Elsevier in Leukemia Research
- Vol. 145, 107560
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALLLeukemia, 2022
- Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic LeukemiaJAMA, 2021
- Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now?Value in Health, 2020
- Immunotherapy in pediatric B-cell acute lymphoblastic leukemiaHuman Immunology, 2019
- Patterns, trends and methodological associations in the measurement and valuation of childhood health utilitiesQuality of Life Research, 2019
- Current outlook of childhood cancer epidemiology in a middle-income country under a public health insurance programPediatric Hematology and Oncology, 2017
- Acute Lymphoblastic Leukemia in ChildrenNew England Journal of Medicine, 2015
- Acute lymphoblastic leukaemiaThe Lancet, 2013
- Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level DataMedical Decision Making, 2013
- Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group studyLeukemia, 2008